Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Meet The Company Giving Patients Access To Unlicensed Medicines

This article was originally published in Scrip

Executive Summary

There is a big unmet need around the ethical management and supply of unlicensed medicines. Their unlicensed status could be due to the products still being experimental, or that the products have been approved in certain territories but not others. And as patients and their physicians become increasingly demanding about access to hard-to-get medicines, a trend which is expected to continue, pharma companies understand they have a responsibility to work with physicians to enable access. And companies such as Clinigen are there to help. Scrip spoke to Clinigen's deputy CEO Shaun Chilton.